Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate

Published 25/06/2025, 15:10
Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate

Investing.com - Kymera Therapeutics (NASDAQ:KYMR) shares declined Wednesday after the company announced that partner Sanofi (NASDAQ:SNY) will not advance their Phase 2-stage IRAK4 degrader KT-474, opting instead to develop a next-generation candidate KT-485 with an improved pre-clinical profile. The company, which holds more cash than debt and maintains a healthy current ratio of 8.49x, saw its stock trading near $45.32.

The decision follows confirmation of transient QTc prolongation for KT-474 in Phase 2 studies, an issue previously identified in Phase 1b trials. KT-474 had been undergoing two Phase 2b trials for atopic dermatitis and hidradenitis suppurativa with data previously expected in 2026.

In a separate announcement, Kymera revealed a new collaboration with Gilead Sciences (NASDAQ:GILD) for novel CDK2 degraders in oncology, though financial details of the partnership were not disclosed.

Leerink Partners maintained an Outperform rating and $60.00 price target on Kymera stock, noting that investor expectations for the IRAK4 program were already low due to historical challenges with IRAK4 inhibitors and uncompelling Phase 1b data.

The firm identified Kymera’s wholly-owned STAT6 degrader KT-621 as the primary focus of its investment thesis, with Phase 1b atopic dermatitis data for the compound expected in the fourth quarter of 2025 representing the next major catalyst for the stock.

In other recent news, Kymera Therapeutics has announced significant developments concerning its collaboration with Sanofi. Sanofi has chosen to advance Kymera’s oral IRAK4 degrader, KT-485, into clinical studies for immuno-inflammatory diseases, while deciding not to proceed with KT-474. This decision follows promising preclinical results for KT-485, which demonstrated increased selectivity and potency. Kymera received a $20 million milestone payment related to these preclinical activities and could earn up to $975 million in further milestones. Additionally, UBS, Stifel, H.C. Wainwright, and Wells Fargo (NYSE:WFC) have all maintained positive ratings on Kymera Therapeutics stock following trial results for another candidate, KT-621. UBS reiterated a Buy rating with a $70 price target, while Stifel raised its target to $68, citing strong trial results. H.C. Wainwright also maintained a Buy rating with a $54 target, emphasizing the reduced risk for future trials. Wells Fargo reaffirmed its Overweight rating, maintaining a $57 target, and highlighted strategic interest in the STAT6 target following a recent deal involving Sanofi.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.